Evolution of transdermal oxybutynin in the treatment of overactive bladder.
about
Luteolin exerts an anticancer effect on NCI-H460 human non-small cell lung cancer cells through the induction of Sirt1-mediated apoptosis.Patient perspectives in the management of overactive bladder, focus on transdermal oxybutynin.Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder.Delivery methods for drugs used in the treatment of overactive bladder.
P2860
Evolution of transdermal oxybutynin in the treatment of overactive bladder.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Evolution of transdermal oxybutynin in the treatment of overactive bladder.
@en
Evolution of transdermal oxybutynin in the treatment of overactive bladder.
@nl
type
label
Evolution of transdermal oxybutynin in the treatment of overactive bladder.
@en
Evolution of transdermal oxybutynin in the treatment of overactive bladder.
@nl
prefLabel
Evolution of transdermal oxybutynin in the treatment of overactive bladder.
@en
Evolution of transdermal oxybutynin in the treatment of overactive bladder.
@nl
P2093
P1476
Evolution of transdermal oxybutynin in the treatment of overactive bladder.
@en
P2093
P304
P356
10.1111/J.1742-1241.2007.01623.X
P577
2008-01-01T00:00:00Z